Patients at Risk for ASCVD, Kidney Failure May Not Get Referral

Why It Matters

Early nephrology involvement could curb ASCVD events and slow progression to end‑stage kidney disease, delivering cost‑effective care and more equitable specialty access.

Key Takeaways

• Over half of CKD patients face intermediate or high 10‑year ASCVD risk.
• More than 90% have low 2‑year kidney failure risk.
• Only 4.2% classified as intermediate/high risk for kidney failure.
• Referral gaps arise from limited nephrology capacity and primary‑care triage.

Pulse Analysis

The intersection of chronic kidney disease (CKD) and atherosclerotic cardiovascular disease (ASCVD) presents a dual‑risk scenario that primary‑care clinicians often manage without specialist input. Recent data from the National Kidney Foundation’s Spring Clinical Meetings examined 7,364 patients with eGFR 15‑59 mL/min/1.73 m² or albuminuria, uncovering that 48.3% sit in an intermediate ASCVD risk bracket and 9.1% are high‑risk over the next decade. Despite this, more than nine out of ten patients exhibit low two‑year kidney‑failure risk, suggesting many are clinically stable yet vulnerable to cardiovascular events.

Systemic barriers drive the referral shortfall. Nephrology clinics face prolonged wait times and constrained staffing, prompting primary‑care providers to prioritize referrals for patients with rapidly declining kidney function or overt end‑stage disease. This triage approach inadvertently sidelines a sizable cohort whose ASCVD risk could be mitigated through co‑management. Modeling studies indicate that proactive nephrology involvement—particularly for those with elevated ASCVD scores—could reduce heart attacks, strokes, and downstream dialysis costs, while also balancing specialty workload by focusing on high‑impact cases.

Future strategies should embed risk‑based referral algorithms into electronic health records, flagging patients who meet intermediate or high ASCVD thresholds despite low kidney‑failure risk. Such tools would enable equitable allocation of nephrology resources, improve cardiovascular outcomes, and potentially lower overall healthcare expenditures. Ongoing research must validate which subpopulations derive the greatest benefit from early specialist engagement, paving the way for policy reforms that integrate cardiometabolic and renal care pathways.